FDA approves Orca Bio's Tregzi for patients undergoing stem cell transplantation
The U.S. FDA has approved Orca Bio's Tregzi, a precision-engineered donor-derived cell therapy designed for patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The therapy aims to reduce the incidence of graft-versus-host disease (GvHD) while maintaining the anti-cancer benefits of transplantation.
Unlike conventional stem cell transplants, Tregzi is manufactured to deliver a highly defined composition of immune cells, including regulatory T cells (Tregs), to improve immune reconstitution and reduce post-transplant complications. The approval was supported by positive Phase III data demonstrating improved GvHD-free, relapse-free survival compared with standard transplantation.
This marks an important milestone for the cell therapy industry, demonstrating that engineered donor cell products can improve one of the longest-standing challenges associated with allogeneic stem cell transplantation. The approval further expands the commercial landscape beyond CAR-T therapies, highlighting the growing diversity of approved cell therapy modalities.
Read more via MedCityNews
Siren Biotechnology secures $8 million to advance cytokine-enhanced gene therapy
Siren Biotechnology has been awarded $8 million in non-dilutive funding from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of SRN-101, the company's lead investigational therapy for high-grade glioma.
The funding will support clinical advancement of the programme without requiring the company to raise additional equity capital. Non-dilutive funding remains an increasingly valuable source of capital in today's challenging investment environment. Support from organisations such as CIRM enables early-stage companies to progress promising therapies while preserving shareholder value and reducing financing risk. The award also reflects growing interest in combining gene therapy with immunotherapy approaches to tackle difficult-to-treat solid tumours.
Read more via GlobeNewswire
FDA expands approval of Casgevy to younger children with sickle cell disease
The FDA has approved an expanded indication for Vertex Pharmaceuticals' Casgevy, allowing the CRISPR-based gene-editing therapy to be used in children aged 5 to 11 years with sickle cell disease who experience recurrent vaso-occlusive crises. Casgevy, developed by Vertex in partnership with CRISPR Therapeutics, was previously approved for patients aged 12 years and older. The expanded approval makes the one-time gene-editing treatment available to younger patients, potentially enabling intervention before years of cumulative organ damage associated with the disease.
By extending treatment to younger patients, regulators are recognising the potential benefits of earlier intervention in genetic diseases, where preventing irreversible complications may significantly improve long-term outcomes. The decision also reinforces confidence in CRISPR-based therapies and highlights how developers are continuing to broaden access following initial regulatory approvals. As more gene therapies move into earlier lines of treatment and younger patient populations, manufacturers will also face increasing demand to scale production and improve patient access worldwide.
Read more via pharmaphorum
)